WASHINGTON, March 24 (UPI) -- The U.S. Food and Drug Administration has issued an alert concerning reports of liver injury in patients taking Prezista.
The FDA said Prezista (darunavir), an anti-retroviral drug used to treat for the human immunodeficiency virus HIV, is suspected of contributing to several hepatic events, including liver failure, destruction of liver tissue, cirrhosis, hepatitis and jaundice.
Healthcare professionals were advised to conduct appropriate laboratory testing prior to and after starting patients on Prezista and to be alert for symptoms of hepatotoxicity, including unexplained fatigue, anorexia, nausea, jaundice, dark urine and liver tenderness.
Patients with chronic hepatitis B or C or those who have pretreatment elevations of liver function tests should be monitored more frequently.
The FDA said it worked with the drug's manufacturer -- Tibotec Therapeutics Inc. of Bridgewater, N.J. -- to include the new hepatotoxicity information on the drug's label.
| Additional News Stories | |
WASHINGTON, Nov. 12 (UPI) --
U.S. President Barack Obama emerged as the world's most powerful man in Forbes magazine's assessment of the world's most powerful people released Thursday.
|
NEW YORK, Nov. 12 (UPI) --
U.S. tennis great Andre Agassi bid farewell Wednesday night on "Late Show with David Letterman" to the mullet-style hairpiece he used to wear.
|
CAPE CANAVERAL, Fla., Nov. 12 (UPI) --
The six astronauts who will be aboard space shuttle Atlantis on its STS-129 mission began their pre-launch activities at Cape Canaveral, Fla., Thursday.
|
|